Novartis completes divestment of ‘front of eye’ ophthalmology assets
Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapies Novartis…
Year: 2023
Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting
Proof-of-concept data supports the clinical evaluation of the Cell Pouch System as a potential treatment…
Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine
The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing…
Deveron Places No, 30th on The Globe and Mail’s Fifth-Annual Ranking of Canada’s Top Growing Companies
Toronto, Ontario–(Newsfile Corp. – September 29, 2023) – Deveron Corp. (TSXV: FARM) is pleased to…
GrafTech Announces Leadership Update
BROOKLYN HEIGHTS, Ohio–(BUSINESS WIRE)–GrafTech International Ltd. (NYSE:EAF) (“GrafTech” or the “Company”) announced today that Marcel…
JFrog Announces CFO Transition
Company Appoints Ed Grabscheid as new CFO, Jacob Shulman to depart as CFO at Fiscal…
TechnipFMC Awarded Flexible Pipe Contract by Petrobras
NEWCASTLE & HOUSTON–(BUSINESS WIRE)–TechnipFMC (NYSE: FTI) has been awarded a significant(1) contract to supply flexible…
New Mountain Finance Corporation Schedules its Third Quarter 2023 Earnings Release and Conference Call
NEW YORK–(BUSINESS WIRE)–New Mountain Finance Corporation (Nasdaq: NMFC) (“New Mountain” or “the Company”) announced today…
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
If approved, odronextamab would be the first and only bispecific antibody approved in both FL…
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
If approved, odronextamab would be the first and only bispecific antibody approved in both FL…
Dyadic to Present at Industry and Investor Events in October
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
Dyadic to Present at Industry and Investor Events in October
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
Outlook Therapeutics® Requests Type A Meeting With FDA
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical…
Outlook Therapeutics® Requests Type A Meeting With FDA
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical…
Portage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
Portage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase…
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase…